tiprankstipranks
Trending News
More News >
Singular Health Group Ltd (AU:SHG)
:SHG
Australian Market

Singular Health Group Ltd (SHG) AI Stock Analysis

Compare
4 Followers

Top Page

AU

Singular Health Group Ltd

(Sydney:SHG)

Rating:54Neutral
Price Target:
AU$0.50
▲(25.00%Upside)
The overall stock score reflects significant financial challenges with ongoing losses and reliance on external financing, offset slightly by positive technical momentum. Valuation is neutral due to the absence of key metrics, and low volatility adds stability.

Singular Health Group Ltd (SHG) vs. iShares MSCI Australia ETF (EWA)

Singular Health Group Ltd Business Overview & Revenue Model

Company DescriptionSingular Health Group Ltd, a medical technology company, develops and commercializes volumetric rendering platform (VRP) for the 3D and virtual reality (VR) visualization of anatomy using standard radiological imagery. It offers 3Dicom Viewer, a cross-platform application that allows its users to interact with standard 2D medical images; 3DicomVSP, an end-to-surgical planning platform; Health Academy, a scalable multi-lingual platform that provides templated curriculum aligned lessons; and GeoVR, a cloud platform for use in the mineral resources sector. The company was founded in 2017 and is headquartered in Subiaco, Australia.
How the Company Makes MoneySingular Health Group Ltd generates revenue primarily through the sale and licensing of its proprietary software products and solutions. The company offers subscription-based models for its software, which provide recurring revenue streams. Additionally, Singular Health collaborates with healthcare institutions, clinics, and research organizations through partnerships and tailored software solutions, further contributing to its earnings. The company's revenue is also bolstered by providing training and support services related to its software offerings.

Singular Health Group Ltd Financial Statement Overview

Summary
Singular Health Group Ltd faces significant financial challenges with continuous losses and declining revenue. While there's some improvement in cost management, the reliance on external financing is a concern. The company needs to improve its profitability and cash generation to enhance financial stability.
Income Statement
35
Negative
Singular Health Group Ltd has experienced declining revenue and persistent losses. The net profit margin is negative, indicating the company is not profitable. Although there is a slight improvement in EBIT and EBITDA margins compared to the previous year, the overall profitability remains weak.
Balance Sheet
45
Neutral
The company's balance sheet shows a moderate level of debt with a Debt-to-Equity Ratio of 0.15, indicating low leverage. However, the Return on Equity is negative due to consistent net losses, and the equity ratio has decreased significantly, reflecting a reduction in shareholder equity.
Cash Flow
40
Negative
Despite a negative operating cash flow, there is a slight improvement in free cash flow compared to the previous year. However, the Free Cash Flow to Net Income Ratio remains unfavorable due to ongoing losses. The company is heavily reliant on financing activities to sustain its operations.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue75.37K90.83K616.14K54.03K193.64K103.86K
Gross Profit-274.44K-2.67M-3.58M-2.11M-1.62M-669.39K
EBITDA-1.76M-2.89M-4.52M-5.72M-2.90M-637.00K
Net Income-1.92M-4.92M-5.39M-5.99M-4.46M-707.59K
Balance Sheet
Total Assets5.11M2.35M3.00M2.14M5.43M668.27K
Cash, Cash Equivalents and Short-Term Investments4.63M1.45M691.51K1.14M4.14M130.55K
Total Debt0.00218.45K2.51M85.66K147.59K745.94K
Total Liabilities311.99K909.59K2.94M391.50K345.10K881.86K
Stockholders Equity4.80M1.44M61.89K1.75M5.08M-213.59K
Cash Flow
Free Cash Flow-1.22M-2.51M-2.49M-2.92M-2.22M-807.48K
Operating Cash Flow-1.22M-2.44M-2.46M-2.91M-1.91M-548.17K
Investing Cash Flow43.14K-3.56K-635.21K-17.12K-610.57K-259.31K
Financing Cash Flow4.35M3.21M2.65M-69.25K6.52M950.69K

Singular Health Group Ltd Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.40
Price Trends
50DMA
0.33
Positive
100DMA
0.28
Positive
200DMA
0.21
Positive
Market Momentum
MACD
0.01
Positive
RSI
55.74
Neutral
STOCH
55.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:SHG, the sentiment is Positive. The current price of 0.4 is above the 20-day moving average (MA) of 0.37, above the 50-day MA of 0.33, and above the 200-day MA of 0.21, indicating a bullish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 55.74 is Neutral, neither overbought nor oversold. The STOCH value of 55.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:SHG.

Singular Health Group Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
HK$15.27B5.80-7.43%4.22%11.60%-21.06%
AUSHG
54
Neutral
AU$120.68M
$53.89M-9.88%
AUALC
55
Neutral
AU$147.72M-5.63%-11.96%7.50%
AUPCK
55
Neutral
AU$73.68M-457.46%21.93%10.34%
AUMDR
53
Neutral
AU$53.11M110.00-8.34%-5.27%50.29%
AUBMT
48
Neutral
AU$69.73M-11.80%14.56%13.36%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:SHG
Singular Health Group Ltd
0.38
0.28
280.00%
TDMMF
Mach7 Technologies Ltd.
0.24
-0.12
-33.33%
AU:BMT
Beamtree Holdings Ltd
0.24
0.02
9.09%
AU:MDR
MedAdvisor Limited
0.08
-0.41
-83.67%
AU:ALC
Alcidion Group Limited
0.10
0.05
100.00%
AU:PCK
PainChek Ltd
0.04
0.01
33.33%

Singular Health Group Ltd Corporate Events

Singular Health Group Ltd Lists New Securities on ASX
Jun 25, 2025

Singular Health Group Ltd has announced the quotation of 1,575,182 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of June 26, 2025. This move is part of the company’s strategy to leverage convertible securities, potentially impacting its financial flexibility and market presence.

Singular Health Group Ltd Announces Quotation of New Securities
Jun 25, 2025

Singular Health Group Ltd has announced the quotation of 22,428,572 ordinary fully paid securities on the ASX, effective June 26, 2025. This move is part of previously announced transactions and signifies a strategic step in enhancing the company’s market presence and liquidity, potentially impacting its operational capabilities and investor engagement.

Singular Health Announces Investor Briefing on New Contract
Jun 20, 2025

Singular Health Group has announced a live investor briefing to discuss a recent USD$1.3 million contract with Provider Network Solutions. This contract is expected to enhance Singular Health’s operations and industry positioning by expanding their reach and capabilities in medical imaging solutions. The briefing will provide insights into the company’s strategic direction and potential implications for stakeholders.

Singular Health Highlights Investment Risks in Latest Presentation
Jun 20, 2025

Singular Health Group Ltd has released a presentation outlining its current operations and investment risks. The company emphasizes that investing in its shares is highly speculative and high risk due to its startup nature. The presentation is informational and not an offer for securities, highlighting the need for prospective investors to conduct their own due diligence.

Singular Health Group Announces Proposed Securities Issue
Jun 19, 2025

Singular Health Group Ltd has announced a proposed issue of securities, including 10 million unlisted options and over 22 million ordinary fully paid shares. This move is aimed at raising capital, which could potentially enhance the company’s operational capabilities and strengthen its position in the healthcare technology market.

Singular Health Group Secures Major Contract and Completes Capital Raising
Jun 19, 2025

Singular Health Group Ltd has signed a USD$1.3 million contract with Provider Network Solutions (PNS) to implement its 3DICOM technology within PNS’s network in Puerto Rico, Florida, and Texas. This agreement marks the first step towards a potential large-scale national deployment across the United States, addressing challenges such as unnecessary duplicate imaging and delays in disease detection. The contract includes the deployment of 1,000 3DICOM licenses and the development of an AI model marketplace and image repository. Additionally, Singular Health has completed an AUD$8 million capital raising to support the national rollout and further product development, with strong backing from institutional investors.

Singular Health Group Initiates Trading Halt for Major Announcement
Jun 17, 2025

Singular Health Group Limited (ASX: SHG) has announced a trading halt on its securities pending a significant announcement related to a capital raising and a material commercial contract. The halt is expected to last until the commencement of normal trading on 19 June 2025 or until the company releases the anticipated announcement. This move suggests potential strategic developments that could impact SHG’s market position and stakeholder interests.

Singular Health Group Announces Director’s Interest Change
Jun 3, 2025

Singular Health Group Ltd has announced a change in the director’s interest, with Denning Chong acquiring 2,000,000 ordinary fully paid shares. This acquisition was made through the conversion of vested performance rights, previously issued under the company’s employee incentive plan. The announcement reflects the company’s ongoing commitment to aligning director interests with shareholder value, potentially impacting its market positioning and stakeholder confidence.

Singular Health Completes Share Placement and Strengthens Financial Position
Jun 1, 2025

Singular Health Group Ltd has successfully completed a placement with Marin and Sons, issuing 4,831,250 new shares to raise $773,000. Additionally, the company raised funds through the exercise of options and issued shares under its employee incentive plan, reflecting a strategic effort to strengthen its financial position and reward contributors. This capital raising supports Singular Health’s mission to enhance its medical technology offerings and maintain its industry positioning, potentially benefiting stakeholders through improved operational capabilities.

Singular Health Group Ltd to Quote New Securities on ASX
Jun 1, 2025

Singular Health Group Ltd has announced the application for quotation of 4,927,728 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its market presence and liquidity. The issuance of these securities follows the exercise of options or conversion of other convertible securities, indicating an active engagement in capital market activities.

Singular Health Group Ltd Issues New Shares Following Option Exercise
May 6, 2025

Singular Health Group Ltd has issued 844,985 fully paid ordinary shares following the exercise of unlisted options, raising $86,988.50. This move reflects the company’s ongoing compliance with the Corporations Act and its strategic efforts to enhance its financial position, potentially impacting its market operations and stakeholder interests.

Singular Health Group Ltd Expands Market Presence with New Securities Quotation
May 6, 2025

Singular Health Group Ltd has announced the quotation of 844,985 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move follows the exercise of options or conversion of other convertible securities, reflecting the company’s ongoing financial activities and potential growth strategy. The announcement signifies an expansion in the company’s market presence and could have implications for its stakeholders by potentially increasing liquidity and shareholder value.

Singular Health Group Announces Director’s Interest Change
Apr 22, 2025

Singular Health Group Ltd has announced a change in the director’s interest, with Howard Digby acquiring 1,000,000 unlisted options as part of his non-executive director remuneration package. This allotment, approved by shareholders, reflects the company’s commitment to aligning its leadership incentives with long-term strategic goals, potentially impacting its market positioning and stakeholder confidence.

Singular Health Group Strengthens Financial Position with Share Issuance
Apr 16, 2025

Singular Health Group Ltd has announced the issuance of 1,030,000 fully paid ordinary shares following the exercise of unlisted options, raising $154,500. This move demonstrates the company’s ongoing efforts to strengthen its financial position and potentially expand its operations. The announcement, authorized by the Board of Directors, indicates compliance with relevant sections of the Corporations Act, ensuring transparency and adherence to regulatory standards. This development could have positive implications for the company’s market presence and stakeholder confidence.

Singular Health Group Ltd Issues New Securities on ASX
Apr 16, 2025

Singular Health Group Ltd has announced the issuance of 1,030,000 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX) under the code SHG. This move is part of the company’s strategy to leverage convertible securities and options, potentially strengthening its financial position and enhancing its market presence.

Singular Health Advances U.S. Market Entry with Key Milestones and Strategic Partnerships
Apr 16, 2025

Singular Health Group Ltd has successfully completed several strategic and technical milestones in the March 2025 quarter, including the completion of a technical proof of concept with Provider Network Solutions (PNS) and the development of the 3Dicom Gateway. These achievements have accelerated the company’s progression to a commercial pilot phase with PNS, strengthening their relationship and positioning Singular Health for commercialization opportunities in the U.S. The company has also secured over $965k in funding, enhancing its financial position and readiness for the upcoming U.S. pilot program. Additionally, Singular Health has engaged with investors through targeted roadshows, attracting interest from institutional investors and reinforcing its commitment to improving medical imaging accessibility.

Singular Health Issues Unquoted Equity Securities
Apr 15, 2025

Singular Health Group Ltd has announced the issuance of unquoted equity securities, specifically unlisted options with varying expiration dates in 2028 and 2029. This strategic move is part of a previously announced transaction, potentially impacting the company’s financial structure and offering stakeholders insights into its long-term operational strategies.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 02, 2025